SOPHiA GENETICS S.A.

NASDAQ:SOPH

Medical - Healthcare Information Services

Healthcare
$7.47 +0.38%

+$0.02 today

Market cap
$635.90M
Beta
0.98
P/E (TTM)
-4.6
EPS (TTM)
-$1.14
52W Low $2.59High $5.70

Volume 0.61M

Average 0.10M

SOPH Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

SOPHiA GENETICS S.A.NASDAQ: SOPH

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $22.57M rose 18.0% year over year, behind the +21.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.7% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Selling, general & admin amounted to 110.2% of revenue in FY2025, down 6.9 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $135.42M (+59.0%) for the fiscal year ending Dec 2026, a step up from the +11.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.57M-6.7% QoQ
Last fiscal yearDec 2025
$85.17M+11.6% YoY
LTMMar 2026
$91.67M+21.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.0%+37.9%+19.9 pp
1 year+11.6%+59.0%+47.4 pp
3-year CAGR+0.4%+35.2%+34.8 pp
5-year CAGR+34.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
85.17M USD
Year-over-year change
+11.6%
4-year CAGR
+4.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SOPH compares with its peers on the latest reported figures

  • SOPH's LTM Mar 2026 selling, general & admin of $91.67M is the 5th highest of the 10 companies compared; the peer median is $89.79M.
  • Its year-over-year change of +21.1% is the 5th highest of 10, against a peer median of +6.5%.
  • Selling, general & admin amounts to 112.9% of revenue for SOPH, versus a peer median of 45.5%.
SOPH Competitors Peer median
Selling, General & Admin for SOPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TEMTempus AI, Inc.LTM Sep 2026$862.5M +35.9%+45.3%57.1%
BLLNBillionToOne, Inc.LTM Jun 2026$180.71M +60.0%—45.5%
CERTCertara, Inc.LTM Mar 2026$149.46M +6.5%+11.9%35.6%
DHDefinitive Healthcare Corp.LTM Mar 2026$132M +3.7%-1.9%55.4%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$91.67M +21.1%+0.4%112.9%
HCATHealth Catalyst, Inc.LTM Mar 2026$89.79M -15.7%-11.9%29.7%
HSTMHealthStream, Inc.LTM Mar 2026$82.3M -0.9%+0.5%26.4%
PSNLPersonalis, Inc.LTM Mar 2026$59.21M +26.4%-5.7%91.8%
NRCNational Research CorporationLTM Mar 2026$57.87M +31.4%+8.7%41.7%
OPRXOptimizeRx CorporationLTM Mar 2026$51.09M -14.1%+0.7%47.6%
Peer median (excluding SOPH) $89.79M+6.5%+0.6%45.5%

Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.45M47.56M62.37M65.17M77.27M
Cost of Revenue15.23M16.31M19.46M21.24M29.46M
Gross Profit25.22M31.25M42.91M43.94M47.81M
Gross Margin62.4%65.7%68.8%67.4%61.9%
Research & Development26.58M35.37M36.97M34.37M33.57M
Selling, General & Admin70.24M84.08M81.72M76.32M85.17M
Operating Expenses96.71M119.08M117.74M110.51M118.74M
Depreciation & Amortization3.61M5.57M8.34M8.6M9.53M
EBITDA(69.24M)(81.38M)(69.57M)(50.76M)(64.4M)
EBITDA Margin-171.2%-171.1%-111.5%-77.9%-83.3%
Operating Income(71.49M)(87.82M)(74.83M)(66.57M)(70.93M)
Operating Margin-176.7%-184.7%-120.0%-102.1%-91.8%
Interest Income20K1.32M4.55M3.36M1.87M
Interest Expense658K639K588K1.91M4.55M
Other Income / Expenses(2.02M)238K(3.67M)5.3M(7.56M)
Income Before Tax(73.51M)(87.59M)(78.5M)(61.27M)(78.49M)
Pre-Tax Margin-181.7%-184.2%-125.9%-94.0%-101.6%
Income Tax Expense168K(136K)486K1.22M512K
Net Income(73.68M)(87.45M)(78.98M)(62.49M)(79M)
Net Margin-182.1%-183.9%-126.6%-95.9%-102.2%
EPS (Basic)(1.33)(1.36)(1.22)(0.95)(1.17)
EPS (Diluted)(1.33)(1.36)(1.22)(0.95)(1.17)
Weighted Avg Shares55.3M64.1M64.75M65.78M67.54M
Weighted Avg Shares (Diluted)55.3M64.1M64.75M65.78M67.54M

SOPHiA GENETICS S.A.

NASDAQ:SOPH

Intrinsic Alpha fair value

Locked

Current Price

$7.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.